share_log

復星醫藥：海外監管公告 - 關於以集中競價交易方式回購股份方案的公告暨回購報告書

FOSUN PHARMA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Mar 26 08:59
Summary by Moomoo AI
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）於2024年3月26日宣布，將通過集中競價交易方式回購公司股份，用於實施股權激勵計劃及/或員工持股計劃。回購股份的資金總額設定在不低於人民幣10億元且不超過20億元，回購價格不超過人民幣30元/股。回購期間自董事會審議通過之日起6個月，即從2024年3月26日至2024年9月25日。公司董事長吳以芳先生表示，此舉是基於對集團發展的信心及價值認可，旨在維護廣大投資者利益、增強投資者信心。復星醫藥已在中國證券登記結算有限責任公司上海分公司開立回購專用賬戶，並將根據相關法律法規及時履行信息披露義務。
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）於2024年3月26日宣布，將通過集中競價交易方式回購公司股份，用於實施股權激勵計劃及/或員工持股計劃。回購股份的資金總額設定在不低於人民幣10億元且不超過20億元，回購價格不超過人民幣30元/股。回購期間自董事會審議通過之日起6個月，即從2024年3月26日至2024年9月25日。公司董事長吳以芳先生表示，此舉是基於對集團發展的信心及價值認可，旨在維護廣大投資者利益、增強投資者信心。復星醫藥已在中國證券登記結算有限責任公司上海分公司開立回購專用賬戶，並將根據相關法律法規及時履行信息披露義務。
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (HEREINAFTER REFERRED TO AS “FUSTAR PHARMACEUTICALS”) ANNOUNCED ON 26 MARCH 2024 THAT IT WILL REPURCHASE SHARES OF THE COMPANY THROUGH A CENTRALIZED TENDER TRANSACTION FOR THE PURPOSE OF IMPLEMENTING THE SHARE INCENTIVE PROGRAM AND/OR EMPLOYEE SHARE PROGRAM. The total amount of the repurchase of shares is set at not less than RMB 10 billion and not more than RMB 20 billion, and the repurchase price does not exceed RMB 30/share. The repurchase period is 6 months from the date of approval of the Board's review, i.e. from 26 March 2024 to 25 September 2024. The Chairman of the Company, Mr. Wu Yifang, said that this move was based on the recognition of the trust and value of the Group's development and aimed at maintaining the interests of the broader investors and strengthening investor confidence. FUSTAR PHARMACEUTICALS HAS OPENED A REPURCHASE SPECIAL ACCOUNT WITH THE SHANGHAI BRANCH OF CHINA SECURITIES REGISTRATION SETTLEMENT LIMITED AND WILL FULFIL ITS INFORMATION DISCLOSURE OBLIGATIONS IN ACCORDANCE WITH RELEVANT LAWS AND REGULATIONS IN A TIMELY MANNER.
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (HEREINAFTER REFERRED TO AS “FUSTAR PHARMACEUTICALS”) ANNOUNCED ON 26 MARCH 2024 THAT IT WILL REPURCHASE SHARES OF THE COMPANY THROUGH A CENTRALIZED TENDER TRANSACTION FOR THE PURPOSE OF IMPLEMENTING THE SHARE INCENTIVE PROGRAM AND/OR EMPLOYEE SHARE PROGRAM. The total amount of the repurchase of shares is set at not less than RMB 10 billion and not more than RMB 20 billion, and the repurchase price does not exceed RMB 30/share. The repurchase period is 6 months from the date of approval of the Board's review, i.e. from 26 March 2024 to 25 September 2024. The Chairman of the Company, Mr. Wu Yifang, said that this move was based on the recognition of the trust and value of the Group's development and aimed at maintaining the interests of the broader investors and strengthening investor confidence. FUSTAR PHARMACEUTICALS HAS OPENED A REPURCHASE SPECIAL ACCOUNT WITH THE SHANGHAI BRANCH OF CHINA SECURITIES REGISTRATION SETTLEMENT LIMITED AND WILL FULFIL ITS INFORMATION DISCLOSURE OBLIGATIONS IN ACCORDANCE WITH RELEVANT LAWS AND REGULATIONS IN A TIMELY MANNER.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more